Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers

ConclusionsThe combination of anlotinib and PD-1 inhibitors demonstrated a promising clinical effect compared to fluoropyrimidine-based chemotherapy in the second-line treatment of refractory advanced BTCs. Liver metastases and CEA levels may serve as predictive factors for identifying patients who may benefit from AP therapy.

http://link.springer.com/10.1007/s12094-024-03425-4

Source: Clinical and Translational Oncology - March 26, 2024 Category: Cancer & Oncology Source Type: research